A Diagnostic Dilemma of Atypical Gallbladder Appearance on Tc-99m HIDA Cholescintigraphy Resolved With SPECT/CT

Endoscopic Papillary Large Balloon Dilation Reduces Further Recurrence in Patients With Recurrent Common Bile Duct Stones: A Randomized Controlled Trial

INTRODUCTION

Up to 60% of patients with common bile duct stone (CBDS) recurrence suffer from further recurrence after endoscopic retrograde cholangiopancreatography (ERCP). There are no effective methods to prevent recurrence in most patients. In this study, we aimed to assess the short-term and long-term efficacies of endoscopic papillary large balloon dilation (EPLBD) for the management of recurrent CBDS in a randomized controlled trial.

METHODS

Consecutive patients with recurrent CBDS were eligible and randomly assigned in a 1:1 ratio to the EPLBD group or the control group. The primary outcome was the CBDS recurrence rate within 2 years after ERCP. The analysis followed the intention-to-treat principle.

RESULTS

From 2014 to 2021, 180 patients with recurrent CBDS were included, with 90 in each group. All patients underwent complete CBDS clearance by 1 or several sessions of ERCP. The rate of complete clearance in 1 session was significantly higher with EPLBD treatment (95.6% vs 85.6%, P = 0.017). During the follow-up, the CBDS recurrence rate within 2 years was significantly lower in the EPLBD group than in the control group (21.1% [19/90] vs 36.7% [33/90], relative risk 0.58, 95% confidence interval 0.36-0.93, P = 0.021). At a median follow-up of approximately 56 months, CBDS recurrence was found in 34.4% of the patients (31/90) in the EPLBD group and 51.1% (46/90) in the control group (hazard ratio 0.57, 95% confidence interval 0.36-0.89, P = 0.012). Multiple recurrences (≥2) were also decreased in the EPLBD group (4.4% vs 18.9%, P = 0.020).

DISCUSSION

During the long-term follow-up, nearly half of the patients with recurrent CBDS experienced stone recurrence after traditional ERCP. Our study was the first to show that EPLBD effectively reduced the recurrence of CBDS.

Bronchobiliary fistula localized by cholescintigraphy with single-photon emission computed tomography

Biliptysis is an important clinical feature to recognize as it is associated with bronchobiliary fistula, a rare entity. Bronchobiliary fistulas have been diagnosed with planar cholescintigraphy. However, cholescintigraphy with single-photon emission computed tomography (SPECT) can better spatially localize a bronchobiliary fistula as compared to planar cholescintigraphy alone, and is useful for preoperative planning if surgical treatment is required. Here, we present the case of a 23-year-old male who developed a bronchobiliary fistula in the setting of posttraumatic and postsurgical infection, which was diagnosed and localized by cholescintigraphy with SPECT.

SPECT/CT unequivocally depicts dilated cystic duct sign on hepatobiliary scintigraphy in acute cholecystitis

The dilated cystic duct sign (DCDS) on hepatobiliary scintigraphy can lead to a false-negative test in patients with acute cholecystitis. Presented is a case of acute gangrenous cholecystitis with probable DCDS on the planar study that was unequivocally delineated on SPECT/CT imaging. SPECT/CT may be useful when planar findings suggest DCDS.

Less commonly used and emerging clinical applications of SPECT-CT in benign and malignant disease

The emergence of hybrid imaging, combining anatomical computed tomography (CT) and functional single-photon emission computed tomography (SPECT), has greatly expanded the armoury available to image disease. Integrated SPECT-CT is a dual-modality technique, which improves the sensitivity and specificity of existing radionuclide studies and enables characterization of equivocal findings detected by conventional imaging. There is a wide range of established and emerging clinical applications for SPECT-CT, which were reviewed in detail at a symposium organized by the British Institute of Radiology in March 2012. A series of articles were commissioned as an adjunct to the symposium and to raise awareness of the clinical utility of this technique. The focus of this article is on less commonly used and emerging clinical applications of hybrid SPECT-CT in a spectrum of benign and malignant conditions. The article will illustrate the incremental value of the technique in a variety of clinical applications.